Prostaglandin E2 (PGE2) in Portal Blood in Patients with Pancreatic Tumor—A Single Institution Series

REFERENCES

• Jemal A, Siegel R, Ward E, Cancer statistics. CA Cancer J Clin. 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Ries LAG, Harkins D, Krapcho M, SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: National Cancer Insitute.
   Google Scholar
• Lowenfels AB, Maisonneuve P, Cavallini G, Pancreatitis and the risk of pancreatic cancer. International pancreatitis study group. N Engl J Med. 1993;328:1433–1437.
   PubMed Web of Science ®Google Scholar
• Talamini G, Bassi C, Falconi M, Early detection of pancreatic cancer following the diagnosis of chronic pancreatitis. Digestion 1999;60:554–561.
   Web of Science ®Google Scholar
• Howes N, Neoptolemos JP. Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis. Gut 2002;51:765–766.
   Google Scholar
• Maisonneuve P, Lowenfels AB. Chronic pancreatitis and pancreatic cancer. Dig Dis. 2002;20:32–37.
   Google Scholar
• Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908–7916.
   PubMed Web of Science ®Google Scholar
• Kokawa A, Kondo H, Gotoda T, Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333–338.
   PubMed Web of Science ®Google Scholar
• Merati K, Siadaty M, Andea A, Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship topathologic and clinical parameters. Am J Clin Oncol. 2001;24:447–452.
   PubMed Web of Science ®Google Scholar
• Okami J, Yamamoto H, Fujiwara Y, Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018–2024.
   PubMed Web of Science ®Google Scholar
• Tucker ON, Dannenberg AJ, Yang EK, Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987–990.
   PubMed Web of Science ®Google Scholar
• Wang HX, Chen QK. Expression and significance of cyclooxygenase-2 in human pancreatic carcinomas. Ai Zheng. 2003;22:649–652. (Abst.)
   Google Scholar
• Kong G, Kim EK, Kim WS, Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol. 2002;17:914–921.
   PubMedGoogle Scholar
• Yip-Schneider MT, Barnard DS, Billings SD. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139–146.
   PubMed Web of Science ®Google Scholar
• Schlosser W, Schlosser S, Ramadani M, Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002;25:26–30.
   PubMedGoogle Scholar
• Maitra A, Ashfaq R, Gunn CR, Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol. 2002;118:194–120.
   PubMed Web of Science ®Google Scholar
• Nijima M, Yamaguchi T, Ishihara T, Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductalpapillary-mucinous tumors of the pancreas. Cancer 2002;94:1565–1573.
   Google Scholar
• Koshiba T, Hosotani R, Miyamoto Y. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26:69–76.
   PubMedGoogle Scholar
• Matsubayashi H, Infante JR, Winter J, Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther. 2007;6:1569–1575.
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Vane JR. Prostaglandins: their dissappearance from and release into the circulation. Nature (Lond.) 1967;216:868–873.
   PubMed Web of Science ®Google Scholar
• Piper PJ, Vane JR; Wyllie JH. Inactivation of prostaglandins by the lungs. Nature (Lond.) 1970;225:600–604.
   PubMed Web of Science ®Google Scholar
• Ding XZ, Tong WG, Adrian TE. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 2001;1:291–299.
   PubMed Web of Science ®Google Scholar
• Williams JA, Shacter E. Regulation of macrophage cytokine production by prostaglandin E2: distinct roles of cyclooxygenase-1 and -2. J Biol Chem. 1997;272:25693–25699.
   PubMed Web of Science ®Google Scholar
• Hotz HG, Hines OJ, Masood R. VEGF antisense therapy inhibits growth and improves survival in experimental pancreatic cancer. Surgery 2005;137:192–199.
   Google Scholar
• Oka M, Inaba A, Uchiyama T, Prostaglandin E2 levels and lymphocyte subsets In portal venous drainage of colorectal cancer. Am J Surg. 1994;167:264–267.
   Google Scholar
• Darwish AA, Sokal E, Stephenne X, Pernament access to the portal system for cellular transplantation using an implantable port device. Liver Transpl. 2004;10:1213–1215.
   PubMed Web of Science ®Google Scholar
• Graham ML, Mutch LA, Rieke EF, Long-term hepatic vascular access in the nonhuman primate for recurrent portal vein infusion. J Invest Surg. 2011;24:59–66.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K. How to define patients at high risk for pancreatic cancer. Pancreatology 2011;11(Suppl. 2):3–6.
   Google Scholar
• Kamisawa T, Takuma K, Tabata T, Long-term follow-up of chronic pancreatitis patients with K-ras mutation in the pancreatic juice. Hepatogastroenterology 2011;58:174–176.
   Google Scholar
• Milella M, Gelibter A, Di Cosimo S, Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133–138.
   PubMedGoogle Scholar